Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
Aim: Carboplatin plus paclitaxel is a more costly chemotherapy regimen than cisplatin plus etoposide; however there have been reports of higher efficacy and less toxicity of this regimen. Thus, this study aimed to assess the cost-effectiveness of these two chemotherapy regimens in advanced non-small...
Saved in:
Main Authors: | Thongprasert S., Permsuwan U., Ruengorn C., Charoentum C., Chewaskulyong B. |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-83355175819&partnerID=40&md5=d442a1b1a609d7e2dc0410d388bf1123 http://www.ncbi.nlm.nih.gov/pubmed/22151987 http://cmuir.cmu.ac.th/handle/6653943832/4558 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Sumitra Thongprasert, et al.
Published: (2018) -
Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer
by: Chewaskulyong B., et al.
Published: (2014) -
Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)